RxDoctor Payments DataLook up a doctor →

Gregory Helmer, MD

Interventional Cardiology · Edina, MNNPI 1144207572

Payments from drug & device makers

$828,127in general payments, 2019–2025

Across 698 payments — averaging $1186.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$626K
  • Medtronic$65K
  • Boston Scientific$55K
  • Abbott$28K
  • Ancora Heart, Inc.$15K
  • Philips North America LLC$14K
  • plus $24K from 15 others

What the payments were for

  • Consulting fees$21,40017%
  • Speaking & faculty fees$49,40939%
  • Travel & lodging$33,31526%
  • Food & beverage$22,11918%
  • Education$240%
  • Entertainment$1080%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$828,127 in reported general payments places this provider in the 90th percentile of 84 interventional cardiology providers in Minnesota.

See all interventional cardiology providers in Minnesota

Medicare billing

Part B allowed, 2024
$94,381
Medicare patients
565
Services billed
1,144

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban41$57,703
BrilintaTicagrelor21$15,521
EntrestoSacubitril/Valsartan13$14,288
Metoprolol Succinate118$2,148
Atorvastatin Calcium81$1,133
Rosuvastatin Calcium70$1,076
Lisinopril54$864
ClopidogrelClopidogrel Bisulfate57$642
Torsemide14$548
Carvedilol37$531
Nitroglycerin36$440
Atenolol16$421
Metoprolol Tartrate18$307
Isosorbide Mononitrate ErIsosorbide Mononitrate19$292
Amiodarone Hcl12$272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$48$15,52121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 84 interventional cardiology providers in Minnesota.

Other interventional cardiology in Edina

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →